drugset / Trial / NCT02489903

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

NCT02489903

Phase 2 Completed 139 enrolled EpicentRx, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen. RRx-001 is administered with autologous blood once weekly followed by or in combination with reintroduction of platinum-based doublet therapy.

Timeline

Start
2015-06
Primary completion
2021-12-06
Completion
2021-12-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule Intravenous
Subject Cisplatin Other / unclassified 60 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 80 mg/m2 Intravenous
Comparator Doxorubicin Other / unclassified
Subject Etoposide Small molecule 80 mg/m2 Intravenous
Subject Etoposide Small molecule 100 mg/m2 Intravenous
Comparator Gemcitabine Small molecule
Comparator Irinotecan Small molecule
Subject NIBROZETONE Other / unclassified 4 mg Intravenous
Subject Paclitaxel Small molecule
Subject Pemetrexed Small molecule
Comparator Vinorelbine Small molecule